Page 23 - 74_01

VOL. 74 (1), 5-27, 2008 ARILESTERASA. ASPECTOS METODOLÓGICOS...

(9) ASZTALOS, B. F.; ROHEIM, P. S.; MILANI, R. L.; LEFEVRE, M.; MCNAMARA, J. R.;
HORVATH, K. V. and SCHAEFER, E. J. (2000): Distribution of Apo A-I-containing
(10) HDL subpopulations in patients with coronary heart disease. Arterioscler.
(11) Thromb. Vasc. Biol. 20: 2670-2676.
(12) BARTER, P. J. (2002): Hugh Sinclair Lecture: The regulation and remodelling
of HDL by plasma factors. Atherosclerosis Suppl. 3: 39-47.
(13) NAVAB, M.; BERLINER, J. A.; SUBBANAGOUNDER, G. and HAMA, S. Y. (2001): HDL
and the inflammatory response induced by LDL-derived oxidized phospho-
(14) lipids. Arterioscler. Thromb. Vasc. Biol. 21: 481-488.
(15) NAVAB, M.; BERLINER, J. A.; WATSON, A. D.; HAMA, S. Y.; TERRITO, M. C.; LUSIS,
(16) A. J., et al. (1996): The Yin and Yang of oxidation in the development of the
fatty streak. A review based on the 1994 George Lyman Duff Memorial Lec-
(17) ture. Arterioscler. Thromb. Vasc. Biol. 16: 831-842.
(18) MINNA, L.; HANNUKSELA, M. E.; BROUSSEAU, S. M.; MEYN, H. N.; GIOVANNI BADER,
(19) R. D.; SHAMBUREK, P. A. and BREWER, H. B. JR. (2002): In vivo metabolism of
(20) apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and
(21) LpE:A-I:A-II. Atherosclerosis. 165: 205-220.
BERGMEIER, C.; SIEKMEIER, R. and GROSS, W. (2004): Distribution spectrum of
(22) paraoxonase activity in HDL fractions. Clin. Chem. 50: 2309-2315.
CANALES, A. and SÁNCHEZ-MUNIZ, F. J. (2003): La paraoxonasa, ¿algo más que
(23) un enzima? Med. CIin. (Barc.). 121: 537-548.
HAREL, M.; AHARONI, A.; GAIDUKOV, L.; BRUMSHTEIN, B.; KHERSONSKY, O.; MEGED,
R.; DVIR, H.; RAVELLI, R. B. G.; MCCARTHY, A.; TOKER L., et al. (2004): Structure
and evolution of the serum paraoxonase family of detoxifying and anti-athe-
rosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419.
PROTEIN DATA BANK http://www.rcsb.org/pdb/navbarsearch.do?newSearch=yes
&isAuthorSearch=no&radioset=All&inputQuickSearch=1v04.
KUO, C. L. and LA DU, B. N. (1998): Calcium binding by human and rabbit
serum paraoxonases. Structural stability and enzymatic activity. Drug Metab.
Disp. 26: 653-660.
YEUNG, D. T.; LENZ, D. E. and CERASOLI, D. M. (2005): Analysis of active-site
amino-acid residues of human serum paraoxonase using competitive subs-
trates. FEBS J. 272: 2225-2230.
SÁNCHEZ-MONTERO, J. M. and NUS, M.: Observaciones sin publicar.
AVIRAM, M.; ROSENBLAT, M.; BILLECKE, S.; EROGUL, J.; SORENSON, R.; BISGAIER, C.
L.; NEWTON, R. S. and LA DU, B. (1999): Human serum paraoxonase (PON1)
is inactivated by oxidized low density lipoprotein and preserved by antioxi-
dants. Free Rad. Biol. Med. 26: 892-904.
AVIRAM, M.; ROSENBLAT, M.; BISGAIER, C. L.; NEWTON, R. S.; PRIMO-PARMO, S. L.
and LA DU, B. N. (1998): Paraoxonase inhibits high density lipoprotein (HDL)
oxidation and preserves its functions, a possible peroxidative role for para-
oxonase. J. CIin. Invest. 101: 1581-1590.
MACKNESS, B.; HINE, D.; LIU, Y.; MASTORIKOU, M. and MACKNESS, M. (2004):
Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothe-
lial cells. Biochem. Biophys. Res. Commun. 318: 680-683.

25